Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Central District of California on behalf of investors who purchased Arrowhead Research Corp. (“Arrowhead Research” or the “Company”) (NasdaqGS: ARWR) stock between August 12, 2014 and October 8, 2014.

For more information, click here: http://zlk.9nl.com/arrowhead-research-arwr.

The complaint alleges that Arrowhead Research materially misstated clinical trial information from its experimental hepatitis B therapy ARC-520 by falsely suggesting that the therapy was more effective than it actually was.

On October 8, 2014, Arrowhead Research released disappointing data for its experimental therapy. That same day, it was reported on TheStreet.com that the Company had misled investors as to the potency and achieved viral load reductions of the therapy. Upon this news shares of Arrowhead Research fell over 43% to close at $7.03 per share on October 8, 2014.

If you suffered a loss in Arrowhead Research you have until December 9, 2014 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/arrowhead-research-arwr.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm’s 28 attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

Copyright Business Wire 2010